Herby Jeanty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Herby Jeanty has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Abinash Mahapatro
SIU School of Medicine, Springfield, IL, USA
8 shared publications - Ehsan Amini-Salehi
Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran
6 shared publications - Elan Mohanty
Mary Medical Center Apple Valley, CA
4 shared publications - Mohit Mirchandani
Montefiore Medical Center Wakefield Campus, Bronx, NY, USA
4 shared publications - Seyyed Mohammad Hashemi
Cardiovascular Research Center Hormozgan University of Medical Sciences Bandar Abbas Iran
4 shared publications - Arezoo Ghazalgoo
Cardiovascular Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
3 shared publications
Latest Publications
- Open Access
- 27 August 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (10) , 6641-6653
The triglyceride-glucose index as a predictor of cardiovascular disease: an umbrella review of meta-analyses
Background: The triglyceride-glucose (TyG) index has gained recognition as a tool for assessing cardiovascular disease risk. This umbrella review synthesized findings from multiple meta-analyses examining the association between the TyG index and cardiovascular outcomes. Methods: In this umbrella review of meta-analyses, we followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Results: A higher TyG index was associated with increased odds of arterial stiffness [categorical: odds ratio (OR) = 1.83, 95% confidence interval (CI): 1.55–2.17, P < 0.01; I 2 = 68%; per 1-unit increase: OR = 1.51, 95% CI: 1.35–1.69, P < 0.01; I 2 = 82%]; coronary artery stenosis (OR = 3.49, 95% CI: 1.71–7.12, P < 0.01; I 2 = 0%); coronary artery calcification (CAC) (highest vs. lowest: OR = 1.66, 95% CI: 1.51–1.82, P < 0.01; I 2 = 0%; continuous: OR = 1.73, 95% CI: 1.36–2.20, P < 0.01; I 2 = 51%); CAC progression (categorical: OR = 1.66, 95% CI: 1.21–2.27, P < 0.01; I 2 = 0%; continuous: OR = 1.47, 95% CI: 1.29–1.68, P < 0.01; I 2 = 41%); and atrial fibrillation (AF) (categorical: OR = 1.98, 95% CI: 1.35–2.91, P < 0.01; I 2 = 92%; continuous: OR = 1.80, 95% CI: 1.50–2.17, P < 0.01; I 2 = 88%). Conclusion: Current meta-analytic evidence suggests that higher TyG index values are associated with several adverse cardiovascular outcomes. However, substantial heterogeneity and the generally low methodological quality of the included meta-analyses limit confidence in the magnitude and clinical applicability of these associations. The TyG index may serve as an adjunctive cardiovascular risk marker, but further high-quality prospective validation is required before routine clinical implementation.
- 27 August 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (10) , 6641-6653
Open AccessThe triglyceride-glucose index as a predictor of cardiovascular disease: an umbrella review of meta-analyses
Background: The triglyceride-glucose (TyG) index has gained recognition as a tool for assessing cardiovascular disease risk. This umbrella review synthesized findings from multiple meta-analyses examining the association between the TyG index and cardiovascular outcomes. Methods: In this umbrella review of meta-analyses, we followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Results: A higher TyG index was associated with increased odds of arterial stiffness [categorical: odds ratio (OR) = 1.83, 95% confidence interval (CI): 1.55–2.17, P < 0.01; I 2 = 68%; per 1-unit increase: OR = 1.51, 95% CI: 1.35–1.69, P < 0.01; I 2 = 82%]; coronary artery stenosis (OR = 3.49, 95% CI: 1.71–7.12, P < 0.01; I 2 = 0%); coronary artery calcification (CAC) (highest vs. lowest: OR = 1.66, 95% CI: 1.51–1.82, P < 0.01; I 2 = 0%; continuous: OR = 1.73, 95% CI: 1.36–2.20, P < 0.01; I 2 = 51%); CAC progression (categorical: OR = 1.66, 95% CI: 1.21–2.27, P < 0.01; I 2 = 0%; continuous: OR = 1.47, 95% CI: 1.29–1.68, P < 0.01; I 2 = 41%); and atrial fibrillation (AF) (categorical: OR = 1.98, 95% CI: 1.35–2.91, P < 0.01; I 2 = 92%; continuous: OR = 1.80, 95% CI: 1.50–2.17, P < 0.01; I 2 = 88%). Conclusion: Current meta-analytic evidence suggests that higher TyG index values are associated with several adverse cardiovascular outcomes. However, substantial heterogeneity and the generally low methodological quality of the included meta-analyses limit confidence in the magnitude and clinical applicability of these associations. The TyG index may serve as an adjunctive cardiovascular risk marker, but further high-quality prospective validation is required before routine clinical implementation.
- Open Access
- 14 July 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (14) , 2103
Artificial Intelligence and Healthcare Policy: A Bibliometric Analysis of Global Research Trends
Background: Artificial intelligence is increasingly influencing health care and policy, yet the global research landscape linking artificial intelligence and health care policy remains underexplored. This study aimed to map publication trends, major contributors, collaboration networks, citation structures, and emerging themes in this field. Methods: A bibliometric analysis was conducted using the Web of Science Core Collection. The search was performed on 3 May 2026, and covered publications from 2000 to 3 May 2026. The final dataset included 347 peer-reviewed English-language original research and review articles. Biblioshiny, VOSviewer, and CiteSpace were used to analyze publication trends, country and institutional contributions, author and journal productivity, collaboration networks, citation and co-citation structures, keyword patterns, and thematic evolution. Results: Publications increased markedly after 2020 and reached their highest annual output in 2025. The 2026 publication count was lower because data for that year were partial at the time of database retrieval. Researchers from 82 countries and 900 institutions contributed to the field, with the United States leading in output, followed by China, England, Canada, and India. Harvard Medical School was the most productive institution, whereas Harvard University had the highest institutional centrality. Frontiers in Public Health published the most articles, and PLOS ONE was the most frequently co-cited journal. The most cited article was “Artificial intelligence and the future of global health.” Key research themes included machine learning, COVID-19, health policy, risk, large language models, interpretable machine learning, neural network-assisted screening, socioeconomic perspectives, and public health applications. Conclusions: Research on artificial intelligence and health care policy has expanded rapidly, particularly in recent years, and is increasingly centered on predictive modeling, public health decision-making, and emerging artificial intelligence technologies. These findings highlight influential contributors, evolving themes, and future directions for researchers, policymakers, and health care leaders.
- 14 July 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (14) , 2103
Open AccessArtificial Intelligence and Healthcare Policy: A Bibliometric Analysis of Global Research Trends
Background: Artificial intelligence is increasingly influencing health care and policy, yet the global research landscape linking artificial intelligence and health care policy remains underexplored. This study aimed to map publication trends, major contributors, collaboration networks, citation structures, and emerging themes in this field. Methods: A bibliometric analysis was conducted using the Web of Science Core Collection. The search was performed on 3 May 2026, and covered publications from 2000 to 3 May 2026. The final dataset included 347 peer-reviewed English-language original research and review articles. Biblioshiny, VOSviewer, and CiteSpace were used to analyze publication trends, country and institutional contributions, author and journal productivity, collaboration networks, citation and co-citation structures, keyword patterns, and thematic evolution. Results: Publications increased markedly after 2020 and reached their highest annual output in 2025. The 2026 publication count was lower because data for that year were partial at the time of database retrieval. Researchers from 82 countries and 900 institutions contributed to the field, with the United States leading in output, followed by China, England, Canada, and India. Harvard Medical School was the most productive institution, whereas Harvard University had the highest institutional centrality. Frontiers in Public Health published the most articles, and PLOS ONE was the most frequently co-cited journal. The most cited article was “Artificial intelligence and the future of global health.” Key research themes included machine learning, COVID-19, health policy, risk, large language models, interpretable machine learning, neural network-assisted screening, socioeconomic perspectives, and public health applications. Conclusions: Research on artificial intelligence and health care policy has expanded rapidly, particularly in recent years, and is increasingly centered on predictive modeling, public health decision-making, and emerging artificial intelligence technologies. These findings highlight influential contributors, evolving themes, and future directions for researchers, policymakers, and health care leaders.
- Open Access
- 8 May 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (19) , e48629
Effects of curcumin on anthropometric measurements in nonalcoholic fatty liver disease: An umbrella meta-analysis study
Background: Metabolic-associated fatty liver disease (MAFLD) affects approximately 30% of the global population and is associated with obesity and metabolic syndrome. Anthropometric indices such as body mass index (BMI), waist circumference (WC), and weight are crucial markers for evaluating the progression of MAFLD. Curcumin, a bioactive compound with anti-inflammatory and antioxidant properties, has been investigated for its potential to improve metabolic outcomes. This umbrella review aimed to systematically evaluate the effects of curcumin supplementation on anthropometric indices in patients with MAFLD, considering epidemiological strength and power analysis. Methods: An umbrella review of meta-analyses from randomized controlled trials was conducted. PubMed, Scopus, and Web of Science were searched up to September 2024. Meta-analyses assessing curcumin’s effects on BMI, weight, and WC in MAFLD patients were included. Quality was assessed using the A Measurement Tool to Assess Systematic Reviews version (AMSTAR-2) tool, and heterogeneity was evaluated using the I 2 statistic. Statistical analyses were performed using R and Stata 18 software. Results: Curcumin supplementation had no significant effect on BMI (standardized mean difference [SMD]: −0.01; 95% confidence interval [CI]: −0.24 to 0.21, P = .91) with low power (1-β = 0.03) and a low epidemiological grade according to GRADE criteria. Similarly, curcumin showed no significant effect on WC (SMD: −0.27; 95% CI: −0.57 to 0.04, P = .08) with high power (1-β = 0.96) but low epidemiological strength. However, curcumin significantly reduced weight (SMD: −0.12; 95% CI: −0.19 to −0.04, P < .01) with moderate power (1-β = 0.56) and moderate epidemiological strength. No significant effect of dose or effect of supplementation duration was found. Conclusion: Curcumin supplementation may result in a statistically detectable but clinically modest reduction in body weight in patients with MAFLD, while showing limited or no efficacy on BMI and waist circumference. The epidemiological strength of the evidence varies across outcomes and is of low to moderate quality. Further well-designed, high-quality randomized controlled trials are needed to confirm the clinical relevance of curcumin’s effects on anthropometric indices.
- 8 May 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (19) , e48629
Open AccessEffects of curcumin on anthropometric measurements in nonalcoholic fatty liver disease: An umbrella meta-analysis study
Background: Metabolic-associated fatty liver disease (MAFLD) affects approximately 30% of the global population and is associated with obesity and metabolic syndrome. Anthropometric indices such as body mass index (BMI), waist circumference (WC), and weight are crucial markers for evaluating the progression of MAFLD. Curcumin, a bioactive compound with anti-inflammatory and antioxidant properties, has been investigated for its potential to improve metabolic outcomes. This umbrella review aimed to systematically evaluate the effects of curcumin supplementation on anthropometric indices in patients with MAFLD, considering epidemiological strength and power analysis. Methods: An umbrella review of meta-analyses from randomized controlled trials was conducted. PubMed, Scopus, and Web of Science were searched up to September 2024. Meta-analyses assessing curcumin’s effects on BMI, weight, and WC in MAFLD patients were included. Quality was assessed using the A Measurement Tool to Assess Systematic Reviews version (AMSTAR-2) tool, and heterogeneity was evaluated using the I 2 statistic. Statistical analyses were performed using R and Stata 18 software. Results: Curcumin supplementation had no significant effect on BMI (standardized mean difference [SMD]: −0.01; 95% confidence interval [CI]: −0.24 to 0.21, P = .91) with low power (1-β = 0.03) and a low epidemiological grade according to GRADE criteria. Similarly, curcumin showed no significant effect on WC (SMD: −0.27; 95% CI: −0.57 to 0.04, P = .08) with high power (1-β = 0.96) but low epidemiological strength. However, curcumin significantly reduced weight (SMD: −0.12; 95% CI: −0.19 to −0.04, P < .01) with moderate power (1-β = 0.56) and moderate epidemiological strength. No significant effect of dose or effect of supplementation duration was found. Conclusion: Curcumin supplementation may result in a statistically detectable but clinically modest reduction in body weight in patients with MAFLD, while showing limited or no efficacy on BMI and waist circumference. The epidemiological strength of the evidence varies across outcomes and is of low to moderate quality. Further well-designed, high-quality randomized controlled trials are needed to confirm the clinical relevance of curcumin’s effects on anthropometric indices.
- Open Access
- 15 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 8748-8756
Exploring the Systemic Immune-Inflammation Index as a novel biomarker for nonalcoholic fatty liver disease: a systematic review and meta-analysis
Background: Nonalcoholic fatty liver disease (NAFLD) represents one of the most prevalent chronic hepatic disorders globally and is intricately associated with metabolic dysregulation and persistent systemic inflammation. The Systemic Immune-Inflammation Index (SII) has emerged as a promising noninvasive indicator for various inflammation-mediated conditions, including NAFLD. This meta-analysis was undertaken to assess the association between SII and NAFLD. Methods: Observational studies identified through a systematic search of PubMed, Web of Science, Embase, and Scopus up to February 2025 that examined the association between SII and NAFLD were considered eligible for inclusion. Quantitative synthesis of the data was conducted through meta-analytic techniques employing a random-effects model to derive pooled effect estimates, thereby accounting for potential heterogeneity across studies. Results: The meta-analysis demonstrated a statistically significant association between higher SII levels and NAFLD. When SII was analyzed as a continuous variable, the pooled effect size was significant (Hedges’ g = 0.11, 95% CI: 0.04–0.18, P < 0.01), indicating elevated SII levels in individuals with NAFLD compared to controls. When evaluated categorically, individuals with high SII values had increased odds of having NAFLD (OR = 1.45, 95% CI: 1.18–1.78, P < 0.01). Statistical power was sufficient to support the validity of the observed associations. Conclusions: SII shows a significant association with NAFLD and may serve as a valuable, noninvasive biomarker for early detection and risk stratification. Despite promising results, the presence of heterogeneity and possible publication bias highlights the need for more standardized and longitudinal research to validate SII’s clinical utility in NAFLD.
- 15 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 8748-8756
Open AccessExploring the Systemic Immune-Inflammation Index as a novel biomarker for nonalcoholic fatty liver disease: a systematic review and meta-analysis
Background: Nonalcoholic fatty liver disease (NAFLD) represents one of the most prevalent chronic hepatic disorders globally and is intricately associated with metabolic dysregulation and persistent systemic inflammation. The Systemic Immune-Inflammation Index (SII) has emerged as a promising noninvasive indicator for various inflammation-mediated conditions, including NAFLD. This meta-analysis was undertaken to assess the association between SII and NAFLD. Methods: Observational studies identified through a systematic search of PubMed, Web of Science, Embase, and Scopus up to February 2025 that examined the association between SII and NAFLD were considered eligible for inclusion. Quantitative synthesis of the data was conducted through meta-analytic techniques employing a random-effects model to derive pooled effect estimates, thereby accounting for potential heterogeneity across studies. Results: The meta-analysis demonstrated a statistically significant association between higher SII levels and NAFLD. When SII was analyzed as a continuous variable, the pooled effect size was significant (Hedges’ g = 0.11, 95% CI: 0.04–0.18, P < 0.01), indicating elevated SII levels in individuals with NAFLD compared to controls. When evaluated categorically, individuals with high SII values had increased odds of having NAFLD (OR = 1.45, 95% CI: 1.18–1.78, P < 0.01). Statistical power was sufficient to support the validity of the observed associations. Conclusions: SII shows a significant association with NAFLD and may serve as a valuable, noninvasive biomarker for early detection and risk stratification. Despite promising results, the presence of heterogeneity and possible publication bias highlights the need for more standardized and longitudinal research to validate SII’s clinical utility in NAFLD.
- Open Access
- 8 August 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (32) , e43641
Prevalence of nonalcoholic fatty liver disease in rheumatoid arthritis: An updated systematic review and meta-analysis
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disorder associated with various comorbidities, including nonalcoholic fatty liver disease (NAFLD). The prevalence of NAFLD in RA patients remains inconsistently reported, necessitating a comprehensive meta-analysis to estimate its true prevalence. This study aimed to assess the prevalence of NAFLD in patients with RA by synthesizing data from multiple studies. Methods: A systematic search was performed across PubMed, Scopus, and Web of Science for studies published up to January 2025. Eligible studies that reported on the prevalence of NAFLD in RA patients were included. A random-effects model was applied, and sensitivity analyses were conducted to test the robustness of the findings. Statistical analyses were performed using Comprehensive Meta-Analysis Software (CMA) version 4 Results: The pooled prevalence of NAFLD/nonalcoholic steatohepatitis (NASH) in RA patients was found to be 22.8% (95% CI = 7.8%–50.8%) with substantial heterogeneity ( I ² = 99.52%). The prediction interval for the prevalence of NAFLD/NASH ranged from 1% to 99%. Subgroup analysis showed varying prevalence rates based on diagnostic modalities: 33.3% for FibroScan, 43.9% for liver biopsy, and 30.5% for ultrasonography. Conclusion: The prevalence of NAFLD is remarkable in RA patients, with varying rates depending on diagnostic methods. The substantial heterogeneity observed across studies, reflected in the wide range of the prediction interval, underscores the need for further studies to provide a more precise estimate. Given the notable prevalence of NAFLD/NASH in RA patients, clinicians are suggested to consider this issue by implementing regular liver screening as a valuable part of RA patient care. More studies are essential to offer a clearer and more consistent understanding of NAFLD/NASH in this population.
- 8 August 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (32) , e43641
Open AccessPrevalence of nonalcoholic fatty liver disease in rheumatoid arthritis: An updated systematic review and meta-analysis
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disorder associated with various comorbidities, including nonalcoholic fatty liver disease (NAFLD). The prevalence of NAFLD in RA patients remains inconsistently reported, necessitating a comprehensive meta-analysis to estimate its true prevalence. This study aimed to assess the prevalence of NAFLD in patients with RA by synthesizing data from multiple studies. Methods: A systematic search was performed across PubMed, Scopus, and Web of Science for studies published up to January 2025. Eligible studies that reported on the prevalence of NAFLD in RA patients were included. A random-effects model was applied, and sensitivity analyses were conducted to test the robustness of the findings. Statistical analyses were performed using Comprehensive Meta-Analysis Software (CMA) version 4 Results: The pooled prevalence of NAFLD/nonalcoholic steatohepatitis (NASH) in RA patients was found to be 22.8% (95% CI = 7.8%–50.8%) with substantial heterogeneity ( I ² = 99.52%). The prediction interval for the prevalence of NAFLD/NASH ranged from 1% to 99%. Subgroup analysis showed varying prevalence rates based on diagnostic modalities: 33.3% for FibroScan, 43.9% for liver biopsy, and 30.5% for ultrasonography. Conclusion: The prevalence of NAFLD is remarkable in RA patients, with varying rates depending on diagnostic methods. The substantial heterogeneity observed across studies, reflected in the wide range of the prediction interval, underscores the need for further studies to provide a more precise estimate. Given the notable prevalence of NAFLD/NASH in RA patients, clinicians are suggested to consider this issue by implementing regular liver screening as a valuable part of RA patient care. More studies are essential to offer a clearer and more consistent understanding of NAFLD/NASH in this population.
- Open Access
- 7 March 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (4) , 2263-2277
The impact of gut microbiome modulation on anthropometric indices in metabolic syndrome: an umbrella review
Background: Metabolic syndrome (MetS) is a complex disorder characterized by a cluster of metabolic risk factors. Recent research highlights the gut microbiome’s role in metabolic regulation, suggesting that modulation through probiotics, prebiotics, and synbiotics may provide a novel approach to managing MetS. This umbrella review aims to integrate insights from existing meta-analyses to explore how changes in gut microbiota influence key body measurement indicators in individuals with MetS. Methods: A systematic search of PubMed, Scopus, and Web of Science databases identified meta-analyses that assessed the impact of probiotics, prebiotics, or synbiotics on anthropometric indices in MetS patients. Results: The results indicated that microbial therapy leads to a significant reduction in body mass index (BMI) (SMD: −0.22; 95% CI: −0.35 to −0.09; P < 0.01) and waist circumference (WC) (SMD: −0.47; 95% CI: −0.80 to −0.15; P < 0.01). However, microbial therapy did not significantly affect body fat mass (SMD: −0.30; 95% CI: −0.64 to 0.02; P = 0.06), body fat percentage (SMD: −0.29; 95% CI: −0.62 to 0.03; P = 0.07), waist-to-hip ratio (SMD: −0.09; 95% CI: −0.46 to 0.28; P = 0.63), and weight (SMD: −0.06; 95% CI: −0.21 to 0.08; P = 0.37). Conclusions: Gut microbial modulation, mainly through probiotics and synbiotics, shows promise in reducing BMI and WC in MetS patients. However, its effects on other anthropometric indices remain uncertain, warranting further high-quality research to fully understand microbial interventions’ therapeutic potential.
- 7 March 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (4) , 2263-2277
Open AccessThe impact of gut microbiome modulation on anthropometric indices in metabolic syndrome: an umbrella review
Background: Metabolic syndrome (MetS) is a complex disorder characterized by a cluster of metabolic risk factors. Recent research highlights the gut microbiome’s role in metabolic regulation, suggesting that modulation through probiotics, prebiotics, and synbiotics may provide a novel approach to managing MetS. This umbrella review aims to integrate insights from existing meta-analyses to explore how changes in gut microbiota influence key body measurement indicators in individuals with MetS. Methods: A systematic search of PubMed, Scopus, and Web of Science databases identified meta-analyses that assessed the impact of probiotics, prebiotics, or synbiotics on anthropometric indices in MetS patients. Results: The results indicated that microbial therapy leads to a significant reduction in body mass index (BMI) (SMD: −0.22; 95% CI: −0.35 to −0.09; P < 0.01) and waist circumference (WC) (SMD: −0.47; 95% CI: −0.80 to −0.15; P < 0.01). However, microbial therapy did not significantly affect body fat mass (SMD: −0.30; 95% CI: −0.64 to 0.02; P = 0.06), body fat percentage (SMD: −0.29; 95% CI: −0.62 to 0.03; P = 0.07), waist-to-hip ratio (SMD: −0.09; 95% CI: −0.46 to 0.28; P = 0.63), and weight (SMD: −0.06; 95% CI: −0.21 to 0.08; P = 0.37). Conclusions: Gut microbial modulation, mainly through probiotics and synbiotics, shows promise in reducing BMI and WC in MetS patients. However, its effects on other anthropometric indices remain uncertain, warranting further high-quality research to fully understand microbial interventions’ therapeutic potential.
- Open Access
- 27 February 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (3) , 1487-1505
Triglyceride-glucose index as a marker in cardiovascular diseases; a bibliometric study and visual analysis
Objective: This study aims to conduct a bibliometric analysis of the triglyceride-glucose (TyG) index in relation to cardiovascular disorders. Methods: Data for the analysis were extracted from the Web of Science Core Collection database on 13 July 2024. We utilized VOSviewer, CiteSpace, and Biblioshiny tools for the analysis. Results: The study revealed a marked increase in research outputs on the TyG index in recent years, peaking with 137 publications in 2023. China emerged as the leading contributor, followed by the USA. The Chinese Academy of Medical Sciences and Peking Union Medical College were among the top contributing institutions. Shouling Wu and Shuohua Chen emerged as the leading authors, with the journal Cardiovascular Diabetology publishing the most articles on this topic. Keyword analysis identified “insulin-resistance” as the most frequently occurring term, followed by “risk.” Cluster analysis identified eleven key research areas, including “percutaneous coronary intervention,” “obesity indicators,” “arterial stiffness,” and “heart failure.” Conclusion: This bibliometric analysis highlights the expanding role of the TyG index in metabolic and cardiovascular research. Key clusters such as percutaneous coronary intervention, obesity indicators, arterial stiffness, heart failure, new-onset hypertension, predicting outcomes, and subclinical coronary artery disease emphasize its wide applicability across diverse clinical settings. The keyword “risk” was the most frequently occurring term, underscoring the importance of the TyG index in cardiovascular risk assessment, alongside its growing use in prognostic applications. These findings reflect the increasing recognition of the TyG index as a pivotal biomarker in cardiovascular medicine and encourage further exploration of its clinical integration.
- 27 February 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (3) , 1487-1505
Open AccessTriglyceride-glucose index as a marker in cardiovascular diseases; a bibliometric study and visual analysis
Objective: This study aims to conduct a bibliometric analysis of the triglyceride-glucose (TyG) index in relation to cardiovascular disorders. Methods: Data for the analysis were extracted from the Web of Science Core Collection database on 13 July 2024. We utilized VOSviewer, CiteSpace, and Biblioshiny tools for the analysis. Results: The study revealed a marked increase in research outputs on the TyG index in recent years, peaking with 137 publications in 2023. China emerged as the leading contributor, followed by the USA. The Chinese Academy of Medical Sciences and Peking Union Medical College were among the top contributing institutions. Shouling Wu and Shuohua Chen emerged as the leading authors, with the journal Cardiovascular Diabetology publishing the most articles on this topic. Keyword analysis identified “insulin-resistance” as the most frequently occurring term, followed by “risk.” Cluster analysis identified eleven key research areas, including “percutaneous coronary intervention,” “obesity indicators,” “arterial stiffness,” and “heart failure.” Conclusion: This bibliometric analysis highlights the expanding role of the TyG index in metabolic and cardiovascular research. Key clusters such as percutaneous coronary intervention, obesity indicators, arterial stiffness, heart failure, new-onset hypertension, predicting outcomes, and subclinical coronary artery disease emphasize its wide applicability across diverse clinical settings. The keyword “risk” was the most frequently occurring term, underscoring the importance of the TyG index in cardiovascular risk assessment, alongside its growing use in prognostic applications. These findings reflect the increasing recognition of the TyG index as a pivotal biomarker in cardiovascular medicine and encourage further exploration of its clinical integration.
- Open Access
- 20 June 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (8) , 4714-4731
The role of gut microbiota augmentation in managing non-alcoholic fatty liver disease: an in-depth umbrella review of meta-analyses with grade assessment
Background and aim: Currently, there are no authorized medications specifically for non-alcoholic fatty liver disease (NAFLD) treatment. Studies indicate that changes in gut microbiota can disturb intestinal balance and impair the immune system and metabolism, thereby elevating the risk of developing and exacerbating NAFLD. Despite some debate, the potential benefits of microbial therapies in managing NAFLD have been shown. Methods: A systematic search was undertaken to identify meta-analyses of randomized controlled trials that explored the effects of microbial therapy on the NAFLD population. The goal was to synthesize the existing evidence-based knowledge in this field. Results: The results revealed that probiotics played a significant role in various aspects, including a reduction in liver stiffness (MD: −0.38, 95% CI: [−0.49, −0.26]), hepatic steatosis (OR: 4.87, 95% CI: [1.85, 12.79]), decrease in body mass index (MD: −1.46, 95% CI: [−2.43, −0.48]), diminished waist circumference (MD: −1.81, 95% CI: [−3.18, −0.43]), lowered alanine aminotransferase levels (MD: −13.40, 95% CI: [−17.02, −9.77]), decreased aspartate aminotransferase levels (MD: −13.54, 95% CI: [−17.85, −9.22]), lowered total cholesterol levels (MD: −15.38, 95% CI: [−26.49, −4.26]), decreased fasting plasma glucose levels (MD: −4.98, 95% CI: [−9.94, −0.01]), reduced fasting insulin (MD: −1.32, 95% CI: [−2.42, −0.21]), and a decline in homeostatic model assessment of insulin resistance (MD: −0.42, 95% CI: [−0.72, −0.11]) (P<0.05). Conclusion: Overall, the results demonstrated that gut microbiota interventions could ameliorate a wide range of indicators including glycemic profile, dyslipidemia, anthropometric indices, and liver injury, allowing them to be considered a promising treatment strategy.
- 20 June 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (8) , 4714-4731
Open AccessThe role of gut microbiota augmentation in managing non-alcoholic fatty liver disease: an in-depth umbrella review of meta-analyses with grade assessment
Background and aim: Currently, there are no authorized medications specifically for non-alcoholic fatty liver disease (NAFLD) treatment. Studies indicate that changes in gut microbiota can disturb intestinal balance and impair the immune system and metabolism, thereby elevating the risk of developing and exacerbating NAFLD. Despite some debate, the potential benefits of microbial therapies in managing NAFLD have been shown. Methods: A systematic search was undertaken to identify meta-analyses of randomized controlled trials that explored the effects of microbial therapy on the NAFLD population. The goal was to synthesize the existing evidence-based knowledge in this field. Results: The results revealed that probiotics played a significant role in various aspects, including a reduction in liver stiffness (MD: −0.38, 95% CI: [−0.49, −0.26]), hepatic steatosis (OR: 4.87, 95% CI: [1.85, 12.79]), decrease in body mass index (MD: −1.46, 95% CI: [−2.43, −0.48]), diminished waist circumference (MD: −1.81, 95% CI: [−3.18, −0.43]), lowered alanine aminotransferase levels (MD: −13.40, 95% CI: [−17.02, −9.77]), decreased aspartate aminotransferase levels (MD: −13.54, 95% CI: [−17.85, −9.22]), lowered total cholesterol levels (MD: −15.38, 95% CI: [−26.49, −4.26]), decreased fasting plasma glucose levels (MD: −4.98, 95% CI: [−9.94, −0.01]), reduced fasting insulin (MD: −1.32, 95% CI: [−2.42, −0.21]), and a decline in homeostatic model assessment of insulin resistance (MD: −0.42, 95% CI: [−0.72, −0.11]) (P<0.05). Conclusion: Overall, the results demonstrated that gut microbiota interventions could ameliorate a wide range of indicators including glycemic profile, dyslipidemia, anthropometric indices, and liver injury, allowing them to be considered a promising treatment strategy.